Minutes ago, ARCA Biopharma Inc (NASDAQ: ABIO) issued a press release announcing that data from a Phase 2B clinical trial has been selected for presentation at a large healthcare conference. Within minutes, the stock was pushing its way well into the green and catching our attention. Today, we’ll talk about:
- The coming presentation;
- what we’re seeing from ABIO as a result; and
- what we’ll be watching for with regard to the stock ahead.
ABIO Is Climbing On A Coming Presentation
As mentioned above, ARCA Biopharma is off to a very strong start in the pre-market hours this morning after announcing a coming presentation. In a press release issued minutes ago, the company said that data from its Atrial Fibrillation Burden substudy of the Phase 2B GENETIC-AF clinical trial have been selected for presentation.
The presentation will come by way of poster and will be offered by ABIO at the American Heart Association 2018 Scientific Sessions. The event will be held in Chicago between November 10 and November 12, 2018.
In the release, ABIO said that Jonathan Piccini, MD, MHS, FACC, FAHA, Associate Professor of Medicine and Director of the Duke Center for Atrial Fibrillation, Duke University Medical Center, will be the presentor of the data.
The presentation is titled, “Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy with Bucindolol vs. Metoprolol for the Prevention of Atrial Fibrillation/Flutter in Heart Failure: Genetic-Af Af Burden Substudy” and will take place on Sunday, November 11, 2018 from 10:30 to 11:45 a.m. CT.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to ARCA Biopharma, the news proved to be overwhelmingly positive. After all, the data that is being presented at a highly trusted medical event in front of potential big-money investors, partners, and other key figures. Not to mention, the acceptance of the data for presentation is a bode of confidence in the company’s work against Atrial Fibrillation. So, it comes as no surprise to see that excited investors are pushing the stock for the top in the market this morning. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:17), ABIO is trading at $0.81 per share after a gain of $0.041 per share or 5.33% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ABIO. In particular, we’re interested in following the story surrounding the company’s continued work to bring new options to patients with Atrial Fibrillation and we’re excited to see the data that is presented at the conference about a week from now. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!